WO2008075370A3 - T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy - Google Patents
T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy Download PDFInfo
- Publication number
- WO2008075370A3 WO2008075370A3 PCT/IL2007/001597 IL2007001597W WO2008075370A3 WO 2008075370 A3 WO2008075370 A3 WO 2008075370A3 IL 2007001597 W IL2007001597 W IL 2007001597W WO 2008075370 A3 WO2008075370 A3 WO 2008075370A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer therapy
- agonist activity
- peptide analogs
- cxcr4
- super
- Prior art date
Links
- 238000011275 oncology therapy Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 title 1
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002483 superagonistic effect Effects 0.000 title 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 239000003183 carcinogenic agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Novel therapeutic uses of T-140 analog peptides and compositions comprising same useful in cancer therapy, specifically for treatinghematopoietic tumors, multiple myeloma, microglioma and glioma, and for increasing the sensitivity of tumor cells to an anti¬ cancer agent such as rapamycin or a derivative thereof are disclosed.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002673484A CA2673484A1 (en) | 2006-12-21 | 2007-12-23 | T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy |
EP07849623A EP2104507A4 (en) | 2006-12-21 | 2007-12-23 | T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy |
US12/520,803 US20100184694A1 (en) | 2006-12-21 | 2007-12-23 | T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy |
US13/360,751 US8765683B2 (en) | 2006-12-21 | 2012-01-29 | T-140 peptide analogs having CXCR4 super-agonist activity for cancer therapy |
IL229151A IL229151A (en) | 2006-12-21 | 2013-10-30 | A t-140 peptide analog having cxcr4 super-agonist activity and an anti-cd20 for lymphoma therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87614506P | 2006-12-21 | 2006-12-21 | |
US60/876,145 | 2006-12-21 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14153703.5A Previously-Filed-Application EP2759302A3 (en) | 2006-12-21 | 2007-12-23 | 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour |
US12/520,803 A-371-Of-International US20100184694A1 (en) | 2006-12-21 | 2007-12-23 | T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy |
US13/360,751 Division US8765683B2 (en) | 2006-12-21 | 2012-01-29 | T-140 peptide analogs having CXCR4 super-agonist activity for cancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008075370A2 WO2008075370A2 (en) | 2008-06-26 |
WO2008075370A3 true WO2008075370A3 (en) | 2016-06-09 |
Family
ID=39536828
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2007/001596 WO2008075369A2 (en) | 2006-12-21 | 2007-12-23 | T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery |
PCT/IL2007/001598 WO2008075371A2 (en) | 2006-12-21 | 2007-12-23 | T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation |
PCT/IL2007/001597 WO2008075370A2 (en) | 2006-12-21 | 2007-12-23 | T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2007/001596 WO2008075369A2 (en) | 2006-12-21 | 2007-12-23 | T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery |
PCT/IL2007/001598 WO2008075371A2 (en) | 2006-12-21 | 2007-12-23 | T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation |
Country Status (7)
Country | Link |
---|---|
US (5) | US20100184694A1 (en) |
EP (5) | EP3011961B1 (en) |
CA (2) | CA2673719C (en) |
ES (1) | ES2842210T3 (en) |
HK (1) | HK1220899A1 (en) |
IL (1) | IL199468A (en) |
WO (3) | WO2008075369A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8435939B2 (en) | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
AU2003261723A1 (en) | 2002-08-27 | 2004-03-19 | Takeda Chemical Industries, Ltd. | Cxcr4 antagonist and use thereof |
EP3011961B1 (en) * | 2006-12-21 | 2020-11-11 | Biokine Therapeutics LTD. | 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation |
US9155780B2 (en) | 2009-02-11 | 2015-10-13 | Yeda Research And Development Co. Ltd. | Short beta-defensin-derived peptides |
MX2011013459A (en) * | 2009-06-14 | 2012-05-08 | Biokine Therapeutics Ltd | Peptide therapy for increasing platelet levels. |
WO2012058241A2 (en) | 2010-10-26 | 2012-05-03 | University Of South Alabama | Methods and compositions for ameliorating pancreatic cancer |
US20130303460A1 (en) * | 2011-01-10 | 2013-11-14 | Biokine Therapeutics Ltd. | Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma |
US20140206629A1 (en) * | 2011-02-17 | 2014-07-24 | Rhode Island Hospital | Stromal Derived Factor Inhibition And CXCR4 Blockade |
TR201910409T4 (en) | 2011-03-11 | 2019-08-21 | Km Biologics Co Ltd | Adjuvant composition containing citrulline. |
WO2012129073A2 (en) * | 2011-03-18 | 2012-09-27 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
EP2841084B1 (en) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer |
WO2014021682A1 (en) * | 2012-08-03 | 2014-02-06 | 가톨릭대학교 산학협력단 | Cd11b+ cx3cr1+ cells, use thereof and method for mass collection of same |
KR101419480B1 (en) * | 2012-08-03 | 2014-07-14 | 가톨릭대학교 산학협력단 | A method for mobilization of CD11b+CX3CR1+ cells |
WO2016185476A1 (en) * | 2015-05-20 | 2016-11-24 | Biokine Therapeutics Ltd. | Methods of obtaining mononuclear blood cells and uses thereof |
EP3322431A2 (en) | 2015-07-16 | 2018-05-23 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
US20180221393A1 (en) | 2015-08-03 | 2018-08-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
EP3368904A1 (en) * | 2015-10-30 | 2018-09-05 | Oxford University Innovation Ltd. | Peptide and biomarker associated with inflammatory disorders, and uses thereof |
AU2017222495B2 (en) | 2016-02-23 | 2019-08-08 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
EP3709917A4 (en) | 2017-11-17 | 2021-07-28 | CryoConcepts LP | Portable electro-mechanical cryosurgical device |
BR112021008797A2 (en) * | 2018-11-09 | 2021-08-31 | Neopep Pharma Gmbh & Co. Kg | POLYPEPTIDES FOR THE TREATMENT OF STRESS, IMMUNORECTION, AND STROKE SYNDROMES |
EP4043041A1 (en) | 2021-02-15 | 2022-08-17 | Technische Universität München | Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US4342828A (en) | 1979-07-20 | 1982-08-03 | Morinaga Milk Industry Co., Ltd. | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
JPS61227526A (en) | 1984-07-25 | 1986-10-09 | Chugai Pharmaceut Co Ltd | Novel csf and method of collecting same |
WO1986004605A1 (en) | 1985-02-08 | 1986-08-14 | Chugai Seiyaku Kabushiki Kaisha | Human granulocyte colony stimulating factor |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
EP1186663A1 (en) | 1985-08-23 | 2002-03-13 | Kirin-Amgen, Inc. | Production of pluripotent granulocyte colony-stimulating factor |
ATE67517T1 (en) | 1985-09-30 | 1991-10-15 | Chugai Pharmaceutical Co Ltd | HUMAN GRANULOCYTE COLONY STIMULATING FACTOR. |
JPH0618778B2 (en) | 1985-10-04 | 1994-03-16 | 中外製薬株式会社 | Leukopenia treatment |
EP0231819B1 (en) | 1986-01-22 | 1992-04-01 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical agent for the treatment of myelogenous leukemia |
ES2039209T5 (en) | 1986-01-22 | 1996-07-16 | Chugai Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOUND THAT PROMOTES THE RESTORATION OF HEMOPOYETIC CAPACITY. |
DK203187A (en) | 1986-04-22 | 1987-10-23 | Immunex Corp | HUMAN G-CSF PROTEIN EXPRESSION |
GR871067B (en) | 1986-07-18 | 1987-11-19 | Chugai Pharmaceutical Co Ltd | Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor |
JPH0725689B2 (en) | 1986-10-07 | 1995-03-22 | 中外製薬株式会社 | Sustained-release preparation containing granulocyte colony-stimulating factor |
JP2618618B2 (en) | 1988-03-04 | 1997-06-11 | 協和醗酵工業株式会社 | Anti-G-CSF derivative, ND28 monoclonal antibody |
DK174044B1 (en) | 1986-12-23 | 2002-05-06 | Kyowa Hakko Kogyo Kk | Polypeptide derived from human granulocyte colony stimulating factor, and method of preparation thereof, DNA encoding said polypeptide, recombinant plasmid containing said DNA, and microorganisms containing said recombinant plasmid ....... |
CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
ATE111921T1 (en) | 1988-06-03 | 1994-10-15 | Chugai Pharmaceutical Co Ltd | HUMAN CRYSTALLINE GRANULOCYTE COLONY STIMULATION FACTOR AND ITS PRODUCTION. |
US5202117A (en) | 1988-08-24 | 1993-04-13 | Koichiro Tsuji | Method of treating thrombi with g-csf |
US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
US5104651A (en) | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
DE68925966T2 (en) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
IL96477A0 (en) | 1989-12-01 | 1991-08-16 | Amgen Inc | Megakaryocyte production |
GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
EP0459516A1 (en) | 1990-06-01 | 1991-12-04 | Kirin-Amgen, Inc. | Oral dosage form of biologically active proteins |
JP3249147B2 (en) | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | Oral preparation containing bioactive protein |
IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
US5250732A (en) | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
FR2686900B1 (en) | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
WO1995010534A1 (en) | 1993-10-14 | 1995-04-20 | Seikagaku Corporation | Polypeptide and anti-hiv agent prepared therefrom |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5492126A (en) | 1994-05-02 | 1996-02-20 | Focal Surgery | Probe for medical imaging and therapy using ultrasound |
DE69840444D1 (en) | 1997-05-23 | 2009-02-26 | Prorhythm Inc | DISMISSABLE FOCUSING ULTRASOUND APPLICATOR OF HIGH INTENSITY |
US6569418B1 (en) | 1997-12-11 | 2003-05-27 | University Of Maryland Biotechnology Institute | Immuno-modulating effects of chemokines in DNA vaccination |
CA2245224A1 (en) | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
CA2305787A1 (en) * | 2000-05-09 | 2001-11-09 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
WO1999047158A2 (en) | 1998-03-13 | 1999-09-23 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
US6178522B1 (en) * | 1998-06-02 | 2001-01-23 | Alliedsignal Inc. | Method and apparatus for managing redundant computer-based systems for fault tolerant computing |
AU5241099A (en) | 1998-07-31 | 2000-02-21 | Trustees Of Columbia University In The City Of New York, The | Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis |
MXPA01003503A (en) * | 1998-10-05 | 2005-01-14 | Pharmexa As | Novel methods for therapeutic vaccination. |
US6576875B1 (en) * | 1998-10-27 | 2003-06-10 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E. V | Method and device for controlling a targeted thermal deposition into a material |
US20060079492A1 (en) | 1999-10-25 | 2006-04-13 | Ahlem Clarence N | Compositions and treatment methods |
US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
GB9902399D0 (en) * | 1999-02-03 | 1999-03-24 | Smithkline Beecham Plc | Compounds |
ES2333399T3 (en) | 1999-03-29 | 2010-02-22 | Shire Canada Inc. | METHODS TO TREAT A LEUKEMIA. |
CA2389979C (en) | 1999-11-24 | 2011-08-16 | Schering Corporation | Methods of inhibiting metastasis |
AU2001236065A1 (en) | 2000-03-03 | 2001-09-12 | Nobutaka Fujii | Antiviral compounds |
JP2003532683A (en) | 2000-05-09 | 2003-11-05 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | CXCR4 antagonist treatment of hematopoietic cells |
EP1323730B1 (en) | 2000-09-05 | 2010-04-21 | Biokine Therapeutics Ltd. | Novel polypeptides and anti-hiv drugs containing the same |
US8435939B2 (en) * | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US7630750B2 (en) | 2001-02-05 | 2009-12-08 | The Research Foundation For The State University Of New York | Computer aided treatment planning |
JP3374917B2 (en) | 2001-02-16 | 2003-02-10 | サンケン電気株式会社 | Switching power supply |
US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
US8774913B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
AU2003261723A1 (en) * | 2002-08-27 | 2004-03-19 | Takeda Chemical Industries, Ltd. | Cxcr4 antagonist and use thereof |
DE10240064A1 (en) | 2002-08-30 | 2004-03-11 | Universitätsklinikum Freiburg | Use of chemokine receptor antagonist for treatment of cancer and inhibition of metastasis, functions as ligand for the CXCR4 receptor |
US7759336B2 (en) * | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
EP1608318A4 (en) | 2003-03-27 | 2009-07-29 | Univ Emory | Cxcr4 antagonists and methods of their use |
WO2004091518A2 (en) * | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
US8545463B2 (en) | 2003-05-20 | 2013-10-01 | Optimyst Systems Inc. | Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device |
CN101444624B (en) | 2004-03-19 | 2012-10-10 | 森永乳业株式会社 | Medicine for cancer therapy |
JP2008509928A (en) * | 2004-08-13 | 2008-04-03 | アノーメド インコーポレイテッド | Chemokine combination to mobilize progenitor / stem cells |
WO2006082588A2 (en) | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Method and device for ophthalmic administration of active pharmaceutical ingredients |
BRPI0615180A2 (en) * | 2005-08-19 | 2011-05-03 | Genzyme Corp | method to intensify chemotherapy |
CN101573441A (en) * | 2005-12-08 | 2009-11-04 | 路易斯维尔大学研究基金会有限公司 | Very small embryonic-like (vsel) stem cells and methods of isolating and using the same |
EP2032691A2 (en) * | 2006-06-15 | 2009-03-11 | Neostem, Inc | Processing procedure for peripheral blood stem cells |
CN101495115A (en) | 2006-08-02 | 2009-07-29 | 健赞股份有限公司 | Combination therapy |
WO2008016141A1 (en) * | 2006-08-04 | 2008-02-07 | Kurume University | Kif-derived peptide capable of binding to hla-a24 molecule |
EP3011961B1 (en) | 2006-12-21 | 2020-11-11 | Biokine Therapeutics LTD. | 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation |
MX2011013459A (en) | 2009-06-14 | 2012-05-08 | Biokine Therapeutics Ltd | Peptide therapy for increasing platelet levels. |
CA2765188A1 (en) | 2009-06-15 | 2010-12-23 | Biokine Therapeutics Ltd. | Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer |
US20130303460A1 (en) | 2011-01-10 | 2013-11-14 | Biokine Therapeutics Ltd. | Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma |
EP2841084B1 (en) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer |
-
2007
- 2007-12-23 EP EP15169576.4A patent/EP3011961B1/en active Active
- 2007-12-23 CA CA2673719A patent/CA2673719C/en active Active
- 2007-12-23 ES ES15169576T patent/ES2842210T3/en active Active
- 2007-12-23 EP EP07849622A patent/EP2094274A4/en not_active Withdrawn
- 2007-12-23 US US12/520,803 patent/US20100184694A1/en not_active Abandoned
- 2007-12-23 US US12/520,811 patent/US8663651B2/en active Active
- 2007-12-23 EP EP07849623A patent/EP2104507A4/en not_active Withdrawn
- 2007-12-23 US US12/520,699 patent/US8455450B2/en active Active
- 2007-12-23 EP EP15166376.2A patent/EP2942059A1/en not_active Withdrawn
- 2007-12-23 CA CA002673484A patent/CA2673484A1/en not_active Abandoned
- 2007-12-23 WO PCT/IL2007/001596 patent/WO2008075369A2/en active Application Filing
- 2007-12-23 WO PCT/IL2007/001598 patent/WO2008075371A2/en active Application Filing
- 2007-12-23 EP EP14153703.5A patent/EP2759302A3/en not_active Withdrawn
- 2007-12-23 WO PCT/IL2007/001597 patent/WO2008075370A2/en active Application Filing
-
2009
- 2009-06-21 IL IL199468A patent/IL199468A/en active IP Right Grant
-
2012
- 2012-01-29 US US13/360,751 patent/US8765683B2/en active Active
-
2013
- 2013-05-08 US US13/889,442 patent/US20140030211A1/en not_active Abandoned
-
2016
- 2016-07-27 HK HK16108975.4A patent/HK1220899A1/en unknown
Non-Patent Citations (5)
Title |
---|
DARASH-YAHANA ET AL.: "Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis''.", FASEB J.;, vol. 18, August 2004 (2004-08-01), pages 1240 - 1242 * |
WEEKES ET AL.: "Publiccations page from the AACR website", PROVIDED IN SUPPORT OF PUBLICATION, 24 February 2006 (2006-02-24), Retrieved from the Internet <URL:http://www.aacr.org/home/scientists/meetings-workshops/aacr-100th-annual-meeting-2009/previous-annual-meetings/annual-meeting-2006/publications.aspx;> [retrieved on 20090619] * |
WEEKES ET AL.: "Stromal derived factor-1 mediates resistance to mTOR inhibition by the preservation of hypoxia inducible factor-1 (HIF-1 ) expression''.", PROC. AMER. ASSOC. CANCER RES., vol. 47, 24 February 2006 (2006-02-24), Retrieved from the Internet <URL:http://www.aacrmeetingabstracts.org/cgi/content/abstrac/2006/1/553-b> [retrieved on 20090613] * |
ZANNETTINO ET AL.: "Elevated Serum Levels of Stromal-Derived Factor-1A Are Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients''.", CANCER RES, vol. 65, no. 5, 1 March 2005 (2005-03-01), pages 1700 - 1709, XP055204495, doi:10.1158/0008-5472.CAN-04-1687 * |
ZHOU ET AL.: "CXCR4 is a Major Chemokine Receptor on Glioma Cells and Mediates Their Survival''.", J. BIOL. CHEM., vol. 277, no. 51, 20 December 2002 (2002-12-20), pages 49481 - 49487 * |
Also Published As
Publication number | Publication date |
---|---|
CA2673484A1 (en) | 2008-06-26 |
EP3011961A1 (en) | 2016-04-27 |
EP2104507A2 (en) | 2009-09-30 |
US20100143334A1 (en) | 2010-06-10 |
CA2673719A1 (en) | 2008-06-26 |
IL199468A (en) | 2017-06-29 |
EP2759302A3 (en) | 2014-11-05 |
US8663651B2 (en) | 2014-03-04 |
EP2094274A4 (en) | 2011-05-11 |
US20100166715A1 (en) | 2010-07-01 |
EP2094274A2 (en) | 2009-09-02 |
EP2104507A4 (en) | 2011-05-25 |
EP3011961B1 (en) | 2020-11-11 |
WO2008075370A2 (en) | 2008-06-26 |
US20140030211A1 (en) | 2014-01-30 |
US20100184694A1 (en) | 2010-07-22 |
WO2008075369A3 (en) | 2009-04-09 |
ES2842210T3 (en) | 2021-07-13 |
WO2008075369A2 (en) | 2008-06-26 |
EP2942059A1 (en) | 2015-11-11 |
US8455450B2 (en) | 2013-06-04 |
EP2759302A2 (en) | 2014-07-30 |
CA2673719C (en) | 2018-07-24 |
US20120207748A1 (en) | 2012-08-16 |
HK1220899A1 (en) | 2017-05-19 |
US8765683B2 (en) | 2014-07-01 |
WO2008075371A3 (en) | 2009-04-16 |
WO2008075371A2 (en) | 2008-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008075370A3 (en) | T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy | |
IL262988A (en) | Targeted therapeutics | |
AU2018256546A1 (en) | Combination therapy with peptide epoxyketones | |
EP3885366A3 (en) | Therapeutic antibodies against ror-1 protein and methods for use of same | |
EP3211001A3 (en) | Superagonists and antagonists of interleukin-2 | |
CL2007002708A1 (en) | COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRIDINA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, CAQUEXY, INFLAMMATORY DISORDERS, AMONG OTHERS. | |
CL2007000161A1 (en) | COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER. | |
NZ597051A (en) | Smac mimetic | |
EP3064220A3 (en) | Compositions and methods for the treatment of infections and tumors | |
NZ602824A (en) | Sparc binding peptides and uses thereof | |
WO2014040074A3 (en) | Compositions and methods for treating cutaneous scarring | |
CL2007002593A1 (en) | COMPOUNDS DERIVED FROM 4-HETEROARIL-PIRIDINA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS REJECTION OF TRANSPLANTED ORGANS, AUTOIMMUNE SYNDROMES AND CANCER. | |
BR112012011332A2 (en) | agents directed to gadd45beta | |
WO2009044273A3 (en) | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response | |
NZ601818A (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers | |
CL2011000119A1 (en) | Compounds derived from triazolo [4,3-a] pyridine; preparation procedure; pharmaceutical composition; and use in the treatment of diseases such as cancer. | |
WO2005116051A3 (en) | Tumor-associated peptides that bind to mhc-molecules | |
EP2926827A3 (en) | Therapeutic Peptidomimetic Macrocycles | |
WO2007130725A3 (en) | Use of hmgb1 for protection against ischemia reperfusion injury | |
WO2007009894A3 (en) | Peptides for use in the treatment of obesity | |
HK1120427A1 (en) | Anti-glypican-3 antibody | |
WO2010057112A3 (en) | Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets | |
WO2011156453A3 (en) | Therapeutic peptides | |
WO2016210376A3 (en) | Therapeutic peptides and methods of use thereof | |
WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07849623 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007849623 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2673484 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12520803 Country of ref document: US |